DiaSys Diagnostic successfully sold majority shares to Mindray
Client
DiaSys Diagnostic Systems GmbH (“DiaSys”)
DiaSys is a large multinational company headquartered in Holzheim, Germany, specialising in the research and development, production and distribution of in-vitro diagnostic products. Since the launch of its first fully liquid, ready-to-use, long-lasting and stable biochemical reagents in 1991, DiaSys has gained a good reputation and market resonance. It enjoys the reputation of being the "father of liquid biochemical reagents" in Europe and the first manufacturer of in-vitro diagnostic reagents in Europe to obtain CE certification.
Project Outline
· Buyer: Shenzhen Mindray Bio-Medical Electronics Co, Ltd, founded in 1991, has one of the most comprehensive product portfolios in the industry, covering three main areas: Life Information and Support, In-vitro Diagnostics and Medical Imaging, meeting clinical needs with safe, efficient and user-friendly "one-stop" products and IT solutions. After years of development, the company has become a leading global provider of medical devices and solutions. It was listed on the GEM Board of the Shenzhen Stock Exchange in October 2018.
· Seller: Gorka Holding GmbH
· Target: 75% of the shares of DiaSys Diagnostic Systems GmbH (“DiaSys”)
· Our Contribution:Successful support as exclusive M&A advisor to the seller, including market screening for potential investors, evaluation of all offers and selection of the buyer, design of the transaction structure, coordination of due diligence and negotiations, support in the preparation of contracts, etc.
· Contract signed on July 28th, 2023
· Closing on November 30th, 2023
· Supporting the seller in the sale of its subsidiary in China in 2014 and in the successful exit of the minority shareholder from the JV in 2022
Highlights
· Rational transaction structure and fulfilment of FDI approval requirement
· Maintained positive communication with potential buyers during the Covid period
